Patents by Inventor Guy Seabrook

Guy Seabrook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
    Publication number: 20060166972
    Abstract: An mGluR4 receptor positive allosteric modulator is useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders such as Parkinson's disease, dyskinesia, tardive dyskinesia, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonian-ALS dementia complex, basal ganglia calcification, akinesia, akinetic-rigid syndrome, bradykinesia, dystonia, medication-induced parkinsonian, Gilles de la Tourette syndrome, Huntington's disease, tremor, chorea, myoclonus, tick disorder, and dystonia.
    Type: Application
    Filed: July 7, 2004
    Publication date: July 27, 2006
    Inventors: P. Conn, Anthony DiLella, Gene Kinney, Michael Marino, Guy Seabrook, David Williams
  • Vanilloid receptor-2 ligands for treating anxiety or depression
    Publication number: 20060025334
    Abstract: The present invention relates to the use of a compound selected from: (a) a VR2 polypeptide; (b) a compound which modulates the activity of a VR2 polypeptide; (c) a polynucleotide encoding a VR2 polypeptide; or (d) an antisense polynucleotide to a polynucleotide encoding a VR2 polypeptide, for the manufacture of a medicament for treating anxiety and/or depression, circadian rhythm disorders, pre-term labor, erectile dysfunction, hypertension and/or schizophrenia.
    Type: Application
    Filed: November 18, 2003
    Publication date: February 2, 2006
    Inventors: Kevin Oliver, Guy Seabrook, Anna Wainwright
  • Transgenic mouse having a disrupted amyloid precursor protein gene
    Patent number: 6187992
    Abstract: The present invention relates to a transgenic nonhuman animal lacking native amyloid precursor protein. The transgenic mouse of the invention may be used in the study of Alzheimer's Disease and disorders involving the central nervous system.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: February 13, 2001
    Assignees: Merck & co., Inc., Merck Frosst Canada & Co.
    Inventors: Hui Zheng, Howard Y. Chen, Myrna E. Trumbauer, Leonardus H. T. van der Ploeg, Guy Seabrook, Dalip Sirinathsinghji